Announcements Trials
Browse Landscape

Status

Recruiting 5Completed 4Not yet recruiting 2Unknown 1Terminated 1Suspended 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 1

Interventions

Cisplatin 352Oxaliplatin 262Capecitabine 258Radiotherapy 240Gemcitabine 223Docetaxel 223Carboplatin 223Drug Therapy 219Cyclophosphamide 219Paclitaxel 205apatinib 201Bevacizumab 196camrelizumab 190Fluorouracil 188sintilimab 133Irinotecan 125Blood Specimen Collection 125Dexamethasone 123Etoposide 119Radiosurgery 118toripalimab 117Surgical Procedures, Operative 115pembrolizumab 112Pemetrexed 108anlotinib 105S 1 (combination) 105Leucovorin 102Surveys and Questionnaires 101Nivolumab 98tislelizumab 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × OTHER × Biological Products × Clear all
NCT04283539 2023-11-13

Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy

National Jewish Health

Unknown
238 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡